Nonviral delivery of self-amplifying RNA vaccines
By A. Geall, A. Verma, G. Otten, C. Shaw, A. Hekele, K. Banerjee, Y. Cu, C. Beard, Luis A. Brito, T. Krucker and 9 more. Proceedings of the National Academy of Sciences of the United States of America, 2012
626 citations recorded by the source corpus.
Subfields: Animal Science and Zoology, Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/6d882e7a75ab43d45ff5548d325fd8343f78bd87
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Arnab Rudra
- Daniel G. Anderson
- Lei Miao
- Min Wu
- G. B. Robb
- Siu-Hong Chan
- Melissa J. Moore
- Piotr S. Kowalski
Citations in the corpus
- mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “Overall, saRNA is an attractive tool for transient expression of the target protein, generating stable cell lines expressing heterologous proteins from continuously replicating RNA, and developing recombinant vaccines.(79,98) For example, Li et al.”
- Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. (2019, positive): “173,181 The resultant RNA, termed replicon, usually contains two different ORFs, with one encoding nonstructural proteins that help RNA capping and replication and the other expressing the antigen that re-places the viral structural protein (Figure 3B).”
- mRNA capping: biological functions and applications (2016, background): “By replacing the capsid proteins genes with the gene of interest, capped and polyadenylated self-amplifying RNA constructs were shown to be more potent in eliciting immune response than vaccination through standard mRNA (172), and efficacious in animal models (150,153,166,173).”
- Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines (2019, positive): “18,19 20 – 22 Here, we describe rational evolution and selection of an improved formulation for IM administration of mRNA, focusing on the impact of the ionizable lipid component as the primary driver of expression and tolerability.”